Novel Antimicrobial Agent Regarded as Next-Generation Antibiotics

Published: 2005-01-24 06:59:00

Updated: 2005-01-24 06:59:00

Cellbiotech Co, a domestic biotechnology venture company, recently announced that its joint clinical study with a pharmaceutical company from China has produced favorable results from using a novel antimicrobial agent.

Conducted in China, results from the clinical study indicate that the nove...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK